Holen Sie sich die Stockscreener-App
28.54
1.47%
-0.52
Schlusskurs vom Vortag:
$29.06
Offen:
$28.71
24-Stunden-Volumen:
493.87K
Relative Volume:
0.39
Marktkapitalisierung:
$3.64B
Einnahmen:
$236.00M
Nettoeinkommen (Verlust:
$-369.00M
KGV:
-8.9669
EPS:
-3.1828
Netto-Cashflow:
$-489.00M
1W Leistung:
-4.08%
1M Leistung:
+0.04%
6M Leistung:
+22.20%
1J Leistung:
+152.93%
1-Tages-Spanne:
$28.52
$29.30
1-Wochen-Bereich:
$28.52
$30.20
52-Wochen-Spanne:
$11.16
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
28.57 | 3.70B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
RCUS Reiterated by Truist Securities -- Price Target Raised to $40 - GuruFocus
Truist raises Arcus Biosciences stock price target on trial data By Investing.com - Investing.com Canada
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences Inc. (RCUS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arcus Biosciences Inc. (RCUS) Peer Comparison – Compare with Others - Value Research
Arcus Biosciences Inc. (RCUS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Why Arcus Biosciences (RCUS) Is Getting Attention Today - Sahm
Arcus Biosciences (RCUS) Slides 3.7% as Biotech Sector Volatility PersistsCatalyst Driven Stocks - dars.gov.et
Arcus Biosciences CAO Azoy sells $84,810 in stock By Investing.com - Investing.com Nigeria
Arcus Biosciences (NASDAQ: RCUS) CAO sells shares from option plan - Stock Titan
Arcus Biosciences CAO Azoy sells $84,810 in stock - Investing.com
Arcus Biosciences (RCUS) officer eyes sale after June plan trades - Stock Titan
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales - Sahm
Investigation launched into Arcus Biosciences o... - Pluang
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders - webull.com
Arcus Biosciences Inc (RCUS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Arcus Biosciences (RCUS) Advances 2.15% as Oncology Pipeline Momentum BuildsEMA Signal - vinanet.vn
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain? - Sahm
Arcus Biosciences (RCUS) Gains Nearly 2% as Shares Trade Near Key Resistance at $30.90Call Dominated - vinanet.vn
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside - TradingView
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - finance.yahoo.com
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript - The Globe and Mail
(RCUS) Volatility Zones as Tactical Triggers - Stock Traders Daily
A New Arcus Employee Receives Options With a $28.72 Exercise Price - Stock Titan
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $29 - Moomoo
Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating - Yahoo Finance
HC Wainwright Issues Optimistic Forecast for RCUS Earnings - MarketBeat
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Arcus Biosciences Q2 Earnings Call Highlights - MarketBeat
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism - Yahoo Finance
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45 - moomoo.com
Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead - Stock Titan
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), NewAmsterdam Pharma Company (NAMS) and Revolution Medicines (RVMD) - The Globe and Mail
Arcus Biosciences Inc (RCUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
RCUS Maintained by Wells Fargo -- Price Target Raised to $26.00 - GuruFocus
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00 - MarketBeat
RCUS Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside - TradingView
Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating - Yahoo Finance
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates - Stocktwits
Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses - webull.com
RCUS Looks 129.7% Overvalued on GF Value™ - GuruFocus
RCUS SWOT Analysis: Financial Struggles and Competitive Pressures Revealed in 10-Q Filing - GuruFocus
Earnings call transcript: Arcus Biosciences tops Q2 2026 estimates, shares rise - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Beats Expectations By $0.17 EPS - MarketBeat
Arcus Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:RCUS) 2026-08-05 - Seeking Alpha
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):